Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Logomix logo — Redefining Therapeutics through Cellular System Engineering

Logomix

Redefining Therapeutics through Cellular System Engineering

Founded 2019 United States San Carlos, United States 10 employees Seed Total: $3.90M Biotechnology

General Information

Company Name Logomix
Founded Year 2019
Location United States San Carlos, United States
Employees 10
Industries Biotechnology
Funding Stage Seed
Business Model B2B, Platform, PaaS
Revenue Model Service Fee, Project Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Logomix. To contact Logomix, visit logomix.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Logomix compare?

A PDF of Logomix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Logomix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Logomix

Logomix Biotechnology is reshaping the landscape of drug development with its pioneering approach to cellular system engineering. The company, founded in 2019 and headquartered in the United States, is marked by its commitment to transforming therapeutics into a scalable information science.

Central to their innovation is the proprietary Geno-Writing™ platform, which allows for the precise and expansive editing of the human genome. This technology is pivotal in Logomix's internal programs, such as their work on Type 1 Diabetes, and serves as a powerful tool for global partners tackling a variety of diseases. Beyond therapeutics, Geno-Writing™ also enhances the Bio-AI ecosystem by generating high-quality iPSC libraries for advanced cell modeling.

Logomix's recent financial milestone—a $3.90M Seed Round on 08 February 2023—was backed by prominent investors including JAFCO Japan, SandHill Angels, Angel Bridge, UTokyo Innovation Platform, and Yasunori Kaneko. This investment underscores confidence in Logomix's potential to industrialize drug discovery, shifting it from an unpredictable art to a reproducible science.

Business keywords: Cellular System Engineering, Drug Development, Geno-Writing™, Digital Genome Design, Type 1 Diabetes Therapeutics, Bio-AI, iPSC Libraries, Synthetic Biology, Genome Engineering, Hypoimmune Cells, Cell Therapy, Regenerative Medicine, Solid Tumor Therapeutics, Gene Editing, TechBio

Services & Products

Large-scale iPSC engineering
Megabase-scale genomic modifications
Ex vivo therapeutic applications

Target Customers

Biopharmaceutical companies Healthcare providers Research institutions Therapeutics developers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $3.90M 5
JAFCO Japan SandHill Angels Angel Bridge
JAFCO Japan, SandHill Angels +3
08 Feb 2023

Logomix Alternatives & Competitors

View All Alternatives
Logomix vs
Pluristyx, Inc.
Pluristyx, Inc. United States

Providing best-in-class mRNA-reprogrammed unedited and gene-modified iPSCs for clinical development

Venture round
24 employees
Biotechnology
Logomix vs
Affini-T Therapeutics
Affini-T Therapeutics United States

Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic driver mut...

Venture round
11 employees
Biotechnology, Health Care
Logomix vs
CERo Therapeutics, Inc.
CERo Therapeutics, Inc. United States

Tumor Cell Clearance Reimagined.

Series A
16 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Logomix

Redefining Therapeutics through Cellular System Engineering
Logomix was founded in 2019.
Logomix is headquartered in San Carlos, United States.
Logomix operates in Biotechnology. Its work centres on Cellular System Engineering, Drug Development, Geno-Writing™ and Digital Genome Design. Its customers include Biopharmaceutical companies, Healthcare providers and Research institutions.
Logomix has a B2B, Platform and PaaS business model. Its revenue comes from Service Fee, Project Based and Licensing.
Logomix has approximately 10 employees.
Logomix has completed 1 funding round, raising a total of $3.90M. The latest funding stage is Seed.
Logomix offers: Large-scale iPSC engineering, Megabase-scale genomic modifications, Ex vivo therapeutic applications.
Top alternatives and competitors to Logomix include Pluristyx, Inc., Affini-T Therapeutics, CERo Therapeutics, Inc., GenScript, Molecular Assemblies, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Logomix and Pluristyx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Logomix, https://bouncewatch.com/company/logomix, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout